Cesar Santa-Maria

Associate Professor

Johns Hopkins University
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (32)

Patients with metastatic triple-negative breast cancer (TNBC) show variable responses to PD-1 inhibition. Efficient patient selection by predictive biomarkers would be desirable, but is hindered by the limited performance of existing biomarkers. Here, we leveraged in-silico patient cohorts generated using a quantitative systems pharmacology model of metastatic TNBC, informed by transcriptomic and clinical data, to explore potential ways to improve patient selection. We tested 90 biomarker candidates, including various cellular and molecular species, by a cutoff-based biomarker testing algorithm combined with machine learning-based feature selection. Combinations of pre-treatment biomarkers improved the specificity compared to single biomarkers at the cost of reduced sensitivity. On the other hand, early on-treatment biomarkers, such as the relative change in tumor diameter from baseline measured at two weeks after treatment initiation, achieved remarkably higher sensitivity and specificity. Further, blood-based biomarkers had a comparable ability to tumor- or lymph node-based biomarkers in identifying a subset of responders, potentially suggesting a less invasive way for patient selection.

Year:

2024

Supplemental Figure 7. B7-H4 and PD-L1 are not mutually exclusive on tumor cells. Data shown are reverse phase protein array expression data of B7-H4 and PD-L1 (SP142, 22C3, or Atezolizumab) from the I-SPY2 patient cohort. Samples were a mixture of TNBC and ER+ tumors and were treated with chemotherapy ± anti-PD-1. Depending on the antibody clone selected to detect PD-L1 expression, B7-H4 had no correlation, or a positive correlation to PD-L1 expression in these tumors. Data analyzed by spearman correlation and shown with linear regression best-fit line. n = 151 patients.

Year:

2024

Supplemental Figure 5. CD45+ gene expression changes from early and later tumor stage between EMT6 control and B7-H4+ tumors. (A) CD45+ cells were isolated from EMT6 control or B7-H4+ tumors 7 days post treatment with isotype control antibody. Differentially expressed genes are shown. n = 6 mice per group. (B) Macrophage function was upregulated in B7-H4+ tumors, but minimal other differences were seen. (C) Differentially expressed genes between control and B7-H4+ tumors at a later stage. n = 12 mice per group. CD45+ cells were harvested when tumors reached 500mm3. (D) Macrophage function remains elevated in B7-H4+ tumors, but minimal differences were detected. Data were analyzed by Wilcoxon rank sum test. Genes with log2 fold change >0.5 or

Year:

2024

Supplemental Figure 5. CD45+ gene expression changes from early and later tumor stage between EMT6 control and B7-H4+ tumors. (A) CD45+ cells were isolated from EMT6 control or B7-H4+ tumors 7 days post treatment with isotype control antibody. Differentially expressed genes are shown. n = 6 mice per group. (B) Macrophage function was upregulated in B7-H4+ tumors, but minimal other differences were seen. (C) Differentially expressed genes between control and B7-H4+ tumors at a later stage. n = 12 mice per group. CD45+ cells were harvested when tumors reached 500mm3. (D) Macrophage function remains elevated in B7-H4+ tumors, but minimal differences were detected. Data were analyzed by Wilcoxon rank sum test. Genes with log2 fold change >0.5 or

Year:

2024

Supplemental Figure 4. B7-H4 expression did not change quantity of infiltrating tumor immune cells in vivo regardless of anti-PD-L1 treatment. Untreated and anti-PD-L1 treated EMT6 tumors ± B7-H4 were dissociated to single cell suspension and subjected to flow cytometry with a 14 (for myeloid cells) or 17 (for T cells) color panel on a CyTEK Aurora. n = 3/group for control and 8/group for treated samples. Data were analyzed by One-way ANOVA with Sidak’s post-hoc test for multiple comparisons between the EMT6 control anti-PD-L1 and EMT6 B7-H4+ anti-PD-L1 treatment groups. One-way ANOVA was not significant between groups. Data were analyzed in GraphPad Prism v10.

Year:

2024

Supplemental Figure 3. B7-H4 was expressed on some tissue immune cells in the C57BL/6 model, but not the BALB/c model. (A) Formalin-fixed, paraffin-embedded sections of BALB/c and C57BL/6 mice were stained for B7-H4, CD45, and DAPI using multiplexed immunofluorescence, or B7-H4 by IHC. CD45+ B7-H4+ cells were observed in spleen and intestine in C57BL/6 mice but not BALB/c mice. (B) Based on morphological characterization, these are likely macrophages. BALB/c spleen, intestine, and other healthy tissues examined (lymph node, fat pad, lung) had no B7-H4+ immune cells. Scale bar 20µm. (C) Flow cytometry of B7-H4+ cells are not present in the BALB/c spleen but are in the C57BL/6 spleen, similar to our findings by mIF. (D) Representation of flow cytometry scatter plots. B7-H4+ immune cells were only found in the C57BL/6 spleen, not bone marrow (b.m.)

Year:

2024

B7-H4 expression is regulated by PI3K signaling. A, Spearman correlations in protein expression from RPPA data collected from patients from the ISPY2 trial. Key positive correlations are called out in blue and key negative correlations are called out in red. B, RPPA data show strong positive correlations between B7-H4 and AKT (pAKT-Ser 473) and strong negative correlations between B7-H4 and PTEN (Ser 380) regardless of tumor hormone receptor status. C, PI3K inhibitor (buparlisib) treatment for 72 hours robustly decreases B7-H4 expression in human MDA-MB-468 breast cancer cells, while MEK inhibitor (trametinib) has no effect. D, Likewise, in MMTV-neu cells, buparlisib reduces B7-H4 expression in dose-dependent manner after 72 hours. Data were analyzed by one-way ANOVA with Dunnet post hoc test for multiple comparisons, P P = 0.0005).

Year:

2024

B7-H4 is associated with immune cold tumors and correlated with worse outcomes. A, Representative TNBC samples (residual disease, post-NAC) categorized on the basis of CD8 T-cell infiltration and localization into ID, MR, SR, and FI. B, B7-H4 is heterogeneously expressed in TNBC. C, ID and MR tumors have the highest level of B7-H4 expression ( n = 69: ID: 19, MR: 17, SR: 14, FI: 19). MR and SR tumors were analyzed by unpaired t test. D, MR and ID tumors also have worse RFS and OS ( n = 69). Data were analyzed by Mantel–Cox test. E, B7-H4 expression directly correlates with worse outcomes in patients ( n = 77; >60%: 16, F, TNBC samples stained with immunofluorescent markers for DAPI, panCK, CD3, and CD8 to identify regions of interest (ROI) for NanoString GeoMX DSP. MR and SR panCK+ ROIs were selected and differential protein expression between tumor samples is shown. G, Within the panCK gated cells, MR tumors had higher EpCAM expression. SR tumors had higher CD44 expression, as well as higher PD-L1. Data shown are log 2 fold change of differentially expressed genes ( P q

Year:

2024

B7-H4 expression does not correlate with resistance to chemotherapy + immunotherapy in human breast tumors. Patients were from the I-SPY2 clinical trial (paclitaxel control and pembrolizumab arms) or the TBCRC 043 clinical trial (carboplatin control and atezolizumab arms). A, In breast tumors from the I-SPY2 clinical trial (control and pembrolizumab arms), B7-H4 expression is higher in TNBC tumors compared with HR+ tumors. Data were analyzed by unpaired t test. B, In the same patient cohort, B7-H4 expression is not higher in grade III tumors compared with grade I (orange dots) or II. Data analyzed by unpaired t test. C and D, B7-H4 expression is not correlated with pCR in tumors regardless of HR status, treated with either paclitaxel or paclitaxel + pembrolizumab (ICI). Data analyzed by unpaired t test. E, EFS in HR + ( n = 89) and TNBC ( n = 62) tumors from the I-SPY2 cohort. Tumors with high B7-H4+ expression (top 33% of patients) have worse EFS when treated with paclitaxel alone and no survival benefit when treated with paclitaxel + ICI. Data were analyzed by log-rank Mantel–Cox test. F, In the metastatic setting, PFS stratified by B7-H4 expression (top and bottom 33% of cohort) from primary breast biopsy or metastatic lesion in patients from the TBCRC 043 trial does not correlate with B7-H4 expression in either control or carboplatin + atezolizumab (ICI) groups. Data were analyzed by log-rank Mantel–Cox test. G and H, We also assessed survival by treatment status. Metastatic tumors (H) from TBCRC 043 with high B7-H4 expression had significantly improved PFS to ICI, and nonmetastatic tumors (I-SPY2) had minimal improvement to ICI (G). Data were analyzed by log-rank Mantel–Cox test. n = 151 patients for A–E and G; n = 91 patients for F and H.

Year:

2024

B7-H4 expression does not correlate with resistance to chemotherapy + immunotherapy in human breast tumors. Patients were from the I-SPY2 clinical trial (paclitaxel control and pembrolizumab arms) or the TBCRC 043 clinical trial (carboplatin control and atezolizumab arms). A, In breast tumors from the I-SPY2 clinical trial (control and pembrolizumab arms), B7-H4 expression is higher in TNBC tumors compared with HR+ tumors. Data were analyzed by unpaired t test. B, In the same patient cohort, B7-H4 expression is not higher in grade III tumors compared with grade I (orange dots) or II. Data analyzed by unpaired t test. C and D, B7-H4 expression is not correlated with pCR in tumors regardless of HR status, treated with either paclitaxel or paclitaxel + pembrolizumab (ICI). Data analyzed by unpaired t test. E, EFS in HR + ( n = 89) and TNBC ( n = 62) tumors from the I-SPY2 cohort. Tumors with high B7-H4+ expression (top 33% of patients) have worse EFS when treated with paclitaxel alone and no survival benefit when treated with paclitaxel + ICI. Data were analyzed by log-rank Mantel–Cox test. F, In the metastatic setting, PFS stratified by B7-H4 expression (top and bottom 33% of cohort) from primary breast biopsy or metastatic lesion in patients from the TBCRC 043 trial does not correlate with B7-H4 expression in either control or carboplatin + atezolizumab (ICI) groups. Data were analyzed by log-rank Mantel–Cox test. G and H, We also assessed survival by treatment status. Metastatic tumors (H) from TBCRC 043 with high B7-H4 expression had significantly improved PFS to ICI, and nonmetastatic tumors (I-SPY2) had minimal improvement to ICI (G). Data were analyzed by log-rank Mantel–Cox test. n = 151 patients for A–E and G; n = 91 patients for F and H.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (20)

Aleksander Popel

Professor

Johns Hopkins University

UNITED STATES
View details

Vijaya Bharti

Research assistant professor

Vanderbilt University

UNITED STATES
View details

Justin M. Balko

Vanderbilt University Medical Center

UNITED STATES
View details

Ravi Varadhan

Professor

Johns Hopkins University

UNITED STATES
View details

brian lehmann

Research Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Payal D. Shah

University of Pennsylvania

UNITED STATES
View details

Xiaopeng Sun

Vanderbilt University

UNITED STATES
View details

Tarah Ballinger

Associate Professor of Medicine

Indiana University School of Medicine

UNITED STATES
View details

Gillian Hirst

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Rosa Isela Gallagher

Senior Research Scientist

George Mason University

UNITED STATES
View details

Luc Van Kaer

Vanderbilt University School of Medicine

UNITED STATES
View details

Juliana Bronzini

Vanderbilt University

UNITED STATES
View details

Laura Esserman

University of California

UNITED STATES
View details

Claudine Isaacs

Professor of Medicine

Georgetown University

UNITED STATES
View details

Laura J. van 't Veer

University of California, San Francisco

UNITED STATES
View details

LAMORNA SWIGART

University of California, San Francisco

UNITED STATES
View details

John T. Wilson

Vanderbilt University

UNITED STATES
View details

Vandana Abramson

Professor of Medicine

-

UNITED STATES
View details

Elizabeth M. Jaffee

Johns Hopkins University School of Medicine

UNITED STATES
View details

Elana Fertig

Assistant Professor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

UNITED STATES
View details